PetDx – The Liquid Biopsy Company for Pets™ is a San Diego-based molecular diagnostics company dedicated to unleashing the power of genomics to improve pet health. The company’s flagship product, OncoK9™, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatic algorithms empowering veterinarians to provide superior care to canine patients.
Location: United States, California, San Diego
Employees: 51-200
Phone: +1 833-464-7297
Total raised: $62M
Founded date: 2019
Investors 3
| Date | Name | Website |
| - | Touch Capi... | touchcapit... |
| 29.01.2022 | Aperture V... | aperturevp... |
| 11.08.2022 | Black Gran... | blackgrani... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 14.12.2021 | Series B | $62M | - |
Mentions in press and media 9
| Date | Title | Description |
| 14.12.2021 | PetDx Raises $62 Million in Series B Financing | La Jolla-based PetDx has raised over $62 million in new capital in a Series B financing round, one of the biggest Series B rounds for a pet startup to date. The new Series B capital infusion brings the company’s total funding to date to $72... |
| 09.12.2021 | PetDx Raises $62M To Get Canine Cancer-Detecting Tech To Vets Across The US | 10 Shares Email Facebook Twitter LinkedIn PetDx, the startup behind an early cancer-detecting blood test for dogs, raised $62 million in its Series B funding round, company leaders told Crunchbase News this week. Subscribe to the Crunchbase... |
| 09.12.2021 | PetDx Raises $62 Million in Series B Financing to Scale Adoption of its Canine Multi-Cancer Early Detection Blood Test, OncoK9 | SAN DIEGO, Dec. 9, 2021 /PRNewswire/ -- PetDx® today announced the completion of its Series B financing with over $62 million in new capital raised, which is one of the biggest Series B rounds for a pet startup; bringing the company's total... |
| 09.12.2021 | PetDx Raises $62M To Get Canine Cancer-Detecting Tech To Vets Across The US | 8 Shares Email Facebook Twitter LinkedIn PetDx, the startup behind an early cancer-detecting blood test for dogs, raised $62 million in its Series B funding round, company leaders told Crunchbase News this week. Subscribe to the Crunchbase ... |
| 09.12.2021 | PetDx, a Connect Cool Company, Gathers $62M in Series B Fundraising to increase adoption of the companies new Canine Multi-Cancer Early Detection Blood Test, OncoK9 | - |
| 09.12.2021 | PetDx Completes $62M Series B Round | SAN DIEGO, CA, PetDx today announced the completion of its Series B financing with over $62 million in new capital raised. >> Click here for more funding data on PetDx >> To export PetDx funding data to PDF and Excel, click ... |
| 31.08.2021 | Liquid biopsy: misplaced faith in early cancer detection? | The trial of Theranos CEO Elizabeth Holmes for defrauding investors about the company’s blood tests highlights a more general reality: huge sums of money are being devoted to develop and promote diagnostic technologies with little evidence ... |
| 18.05.2021 | PETCO HEALTH AND WELLNESS COMPANY, INC. Petco says: B*rk Cancer! The Health + Wellness Company Introduces Groundbreaking Liquid Biopsy Test for Pets, Launches 'Together Strong' Social Awareness Campa... | SAN DIEGO, May 18, 2021 /PRNewswire/ -- Petco Health and Wellness Company, Inc. (NASDAQ: WOOF), a complete partner in pet health and wellness, today launched Together Strong, a pet cancer awareness campaign that brings two- and four-legged ... |
| 18.05.2021 | With Petco’s help, cutting-edge cancer detection tech now available for dogs | Twenty-eight days after learning that his 4-year-old dog, Poppy, had advanced pancreatic cancer, human genomics expert Daniel Grosu started PetDx to apply the latest in oncology research to pets. A little more than two years later, the form... |